Pharvaris soars on mid-stage data for severe swelling condition, raises $300M
Pharvaris immediately announced the pricing of a $300 million offering on Wednesday after disclosing positive mid-stage data on its oral drug for a rare, inherited disorder that leads to severe swelling attacks.
The Swiss biotech said its twice-daily capsule for treating and preventing hereditary angioedema (HAE) attacks met the primary endpoint in a 34-patient Phase II study. Known as CHAPTER-1, the transatlantic trial is still on clinical hold in the US but has continued running in Canada and Europe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.